Form 4: Clene Inc. Director Matthew Kiernan Acquires Stock Options

Director Matthew Kiernan acquired 2,559 stock options in Clene Inc. on October 2, 2024, vesting immediately.

Summary

• On October 2, 2024, Matthew Kiernan, a director of Clene Inc., was granted stock options to purchase 2,559 shares of Clene Inc. common stock.
• The options were granted under the Clene Inc. Amended 2020 Stock Plan.
• The exercise price for the options is $4.89 per share.
• The options vest immediately upon grant and expire on October 1, 2034.
• Following the transaction, Kiernan directly owns 2,559 derivative securities.

Sentiment

Score: 7

Explanation: The document indicates a standard transaction of stock options being granted to a director, which is generally viewed neutrally to positively as it aligns interests. There are no red flags or negative indicators.

Positives

• The immediate vesting of the options suggests confidence in the director's continued contribution to the company.
• The grant of options aligns the director's interests with those of the shareholders.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term performance and align the interests of the director with those of the shareholders.
• Comparable companies often use similar stock plans to attract and retain talent.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment, as it aligns the director's interests with the company's long-term success.

Key Dates